PackGene Biotech, a frontrunner in Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) services, excels in delivering advanced solutions in adeno-associated virus vectors (AAV), mRNA, plasmid DNA, and lentiviral vector (LVV) services. Our expertise extends to early-stage drug discovery, preclinical development, and Cell and Gene Therapy trials, where we offer cost-effective, reliable, and scalable production options. Our π-Alpha 293 AAV High-yield Platform revolutionizes AAV production, boosting yields by up to 10 times compared to conventional methods. This innovation enables us to produce AAV batches up to 1E+17vg, effectively fulfilling the demands of most commercial and clinical projects. In addition to AAV services, PackGene offers customized, scalable plasmid DNA solutions suitable for discovery science, preclinical, and clinical projects, regardless of their size. Our comprehensive approach includes end-to-end design, production, and manufacturing of both new and existing plasmids. With our GMP plasmid Manufacturing Platform, we can scale production from 5L to 200L. We also provide extensive support in process development, analytical development, and cell banking, specifically for AAV, LVV, and plasmid projects, encompassing USP, DSP, and other analytical services. Moreover, PackGene specializes in tailor-made mRNA and LNP solutions, supporting drug and vaccine development through the entire research and GMP production spectrum. At PackGene, our commitment is to drive innovation and progress in biotechnology and healthcare, offering state-of-the-art solutions that align with the dynamic needs of this field.
Oncomed Manufacturing a.s.
We are part of CDMO medac group – your reliable partner specialized in aseptic processing of injectables in clinical and commercial scale. We work is strategic partnership with our clients to provide customized solutions for aseptic manufacturing. | CDMO committed to delivering reliable, flexible support across the entire pharmaceutical value chain. Our capabilities include: • Manufacturing high- and low-potency injectables (vials and syringes) for international markets • Production of small- and large-molecule therapeutics, including complex biologics such as antibody-drug conjugates (ADCs) and oligonucleotides • Scalable batch production, tailored from clinical development through to full commercial supply | x
OmniaBio
OmniaBio Inc. is a specialized cell and gene therapy CDMO with a vision to manufacture a disease-free world. OmniaBio provides comprehensive services to therapeutic developers from early process development through to commercial manufacturing. As a CCRM subsidiary, OmniaBio builds on over a decade of expertise in regenerative medicine and advanced therapies, offering its clients extensive leadership in immune cell-based therapies, induced pluripotent stem cell-based therapies, and lentiviral vectors. With current clinical manufacturing capabilities, and a commercial manufacturing facility opening this summer, OmniaBio is poised to meet the surging global manufacturing demand, enabling access to transformative treatments for patients around the world. Visit us at www.omniabio.com. | OmniaBio is redefining the future of cell therapy manufacturing through its proprietary AI-powered Intelligent Factory™. Purpose-built to accelerate discoveries and industrialize production, the Intelligent Factory™ integrates artificial intelligence and automation across the entire manufacturing lifecycle. With a focus on autologous CAR-T and other advanced therapies, OmniaBio’s platform enables scalable, efficient, and high-fidelity production by embedding predictive analytics, robotic bioprocessing, and digital quality systems into a unified, closed-loop system. This approach not only enhances throughput and consistency but also positions OmniaBio as a next-generation CDMO partner for innovators seeking to bring life-saving therapies to patients faster. | OmniaBio Inc. is a subsidiary of the Centre for Commercialization of Regenerative Medicine (CCRM), which was founded in 2011 to support the development and commercialization of cell and gene therapies and regenerative medicine technologies. Since 2016, we have offered contract development and manufacturing organization (CDMO) services to our clients which draws on the extensive resources of both CCRM and various partners with a team comprised of approximately 300+ professionals, scientists, and engineers, with 60+ PhDs. OmniaBio and CCRM have a strong history in establishing and fostering long-term partnerships with clients, and our deep expertise and state-of-the-art facilities are ideally suited to projects requiring scale-up in various bioreactor geometries, process optimization, and bioprocess engineering. Our services are tailored to each client’s needs to enable the best possible value and outcomes, whether that’s quick entry into the clinic or developing a more optimized process to enable high throughput for clinical manufacturing. Once OmniaBio’s new facility begins opening in late 2024, it will be Canada’s first commercial-scale CDMO dedicated to cell and gene therapies. Based at the McMaster Innovation Park, OmniaBio will anchor a biomanufacturing centre of excellence and open in three phases between 2024 and 2027. Benefitting from CCRM’s existing infrastructure and expertise, OmniaBio will serve the full continuum of process and analytical development and manufacturing capabilities spanning preclinical process development through to commercial stage manufacturing.
Olon SpA
Olon Group is a global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and generic markets, integrating chemical synthesis and biological processes while always embracing the highest international safety, quality, and environmental standards. With one of the longest track records of the API industry, having deep development expertise and a broad set of advanced technologies, we are the partner of choice which enables our client’s molecules to enter the market successfully. Olon has a global network of 11 manufacturing sites and 7 R&D centers across the globe. Thanks to our 2,300 employees, including 300 highly experienced and qualified R&D experts, we represent a highly innovative and reliable partner. At Olon, expertise and competent flexibility throughout the organization help build successful outcomes for our clients in custom chemical synthesis and microbial fermentation, while always maintaining the highest levels of safety, quality, and environmental compliance. | Olon Group is a global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and generic markets, integrating chemical synthesis and biological processes while always embracing the highest international safety, quality, and environmental standards. With one of the longest track records of the API industry, having deep development expertise and a broad set of advanced technologies, we are the partner of choice which enables our client’s molecules to enter the market successfully. Olon has a global network of 14 manufacturing sites and 9 R&D centers across the globe. Thanks to our 2,800 employees, including over 350 highly experienced and qualified R&D experts, we represent a highly innovative and reliable partner. At Olon, expertise and competent flexibility throughout the organization help build successful outcomes for our clients in custom chemical synthesis and biological processes, while always maintaining the highest levels of safety, quality, and environmental compliance. | Olon Group is a global CDMO delivering integrated development and GMP manufacturing services for small‑molecule APIs, biologics and ADCs. The Group combines extensive R&D capabilities—with 14 R&D centers and over 300 scientists—with a robust industrial platform, including 14 GMP manufacturing sites across Europe, the US and India. Olon’s expertise spans chemical synthesis, fermentation, mammalian technologies and bioconjugation, enabling seamless support from early development through commercial supply. Headquartered in Rodano (Milan), Italy, Olon offers a strong international footprint, deep scientific know‑how and a solid regulatory track record to support innovative biotech and pharmaceutical partners worldwide.
OcyonBio
OcyonBio is a game-changing company that offers an innovative solution to the challenges faced by life science organizations in manufacturing and development. We provide dedicated autonomous manufacturing capacity, along with an interconnected infrastructure and cutting-edge systems, to support every stage of the product lifecycle—from early development and pre-clinical phases to clinical trials and commercial production. Unlike traditional approaches, OcyonBio operates as a next-generation cGMP incubator space, boasting a comprehensive range of regulatory capabilities and abundant resources. Our goal is to empower our partners with the necessary tools and support to generate critical CMC data, facilitating smooth and efficient regulatory applications. With OcyonBio, companies can bid farewell to the costly and time-consuming process of building their own facilities. We offer a flexible solution that safeguards intellectual property, streamlines project schedules, optimizes resource allocation, and minimizes the risks associated with new product introduction. By eliminating the need for expensive infrastructure, we reduce overall costs, freeing up resources that can be allocated towards research, development, and innovation. Our manufacturing and development spaces are carefully designed to operate autonomously, ensuring maximum efficiency and productivity. At the same time, they remain interconnected with essential systems to meet the clinical and commercial requirements of our partners. This interconnectedness enables seamless collaboration and information flow, further enhancing the success of your projects. Partnering with OcyonBio means gaining access to a state-of-the-art facility without the burden of construction costs, while enjoying the flexibility to adapt and scale operations according to your needs. We empower you to focus on what matters most—advancing your life science initiatives—while we take care of the manufacturing and development processes. Experience the future of manufacturing and development with OcyonBio. Together, we will revolutionize the life sciences industry, unlocking new possibilities and achieving groundbreaking results. Contact us today to embark on a transformative journey towards success. | OcyonBio redefines innovation in life sciences manufacturing and development. Our tailored solutions address key industry challenges, offering dedicated autonomous manufacturing capabilities and a seamlessly integrated infrastructure. By covering every stage of the product lifecycle, from early development to commercial production, we streamline the path to market success. As pioneers of next-generation cGMP incubator spaces, OcyonBio provides expansive regulatory expertise and abundant resources. Our mission is to equip our partners with essential tools for generating critical CMC data, ensuring efficient regulatory submissions. Choose OcyonBio and say goodbye to the burdens of constructing your own facilities. Our flexible, secure solutions protect intellectual property, enhance project timelines, and optimize resource use, all while minimizing risk during new product introductions. Our approach not only cuts costs but also reallocates savings to foster further research, development, and innovation. Our facilities are designed for peak efficiency and productivity, maintaining connectivity with vital systems to support both clinical and commercial demands. This integration fosters unparalleled collaboration and information exchange, propelling your projects forward. By partnering with OcyonBio, you gain access to cutting-edge facilities without the overhead of construction costs, coupled with the agility to scale operations as needed. Focus on advancing your initiatives; we’ll handle the complex manufacturing and development logistics. Discover the future of life science manufacturing with OcyonBio. Join us in revolutionizing the industry, unlocking new possibilities, and achieving extraordinary outcomes. Contact us today to start your transformative journey toward success. | OcyonBio – Empowering Innovation in Advanced Therapies Headquartered in Aguadilla, Puerto Rico, OcyonBio is a next-generation contract development and manufacturing organization (CDMO) specializing in the development and commercial manufacturing of biologics, cell and gene therapies (CGT), and aseptic drug products. With a foundation built on flexibility, speed, and regulatory excellence, OcyonBio provides integrated solutions for companies developing complex, life-saving therapies. Our Mission To enable biotechnology innovators to bring breakthrough therapies to market faster and more efficiently by providing world-class infrastructure, tailored contract development and manufacturing organization (CDMO) services, and a unique partnership model that empowers scientific teams. Our Services OcyonBio offers a comprehensive suite of services to support the entire development lifecycle: 1. Biologics and CGT Manufacturing • Cell Therapy: Autologous and allogeneic platforms, including CAR-T, TCR, and stem cell-based therapies. • Gene Therapy: Viral vector production (AAV, LV), plasmid DNA production, and fill-finish. • Biologics Drug Substance Manufacturing: Monoclonal antibodies and other recombinant proteins produced using mammalian expression systems (e.g., CHO). • GMP Suites: Modular, BSL-2 compliant cleanroom spaces for Phases I–III and commercial production. 2. Aseptic Fill & Finish • State-of-the-art isolator-based systems for vial and syringe filling. • Flexible batch sizes support clinical through commercial-scale products. 3. Analytical Development & Quality Control • Custom assay development for identity, purity, potency, and safety. • In-house microbiology, molecular biology, and biochemical analytics. • Stability studies, method validation, and release testing. 4. Regulatory & Quality Support • Full cGMP compliance under FDA and EMA guidelines. • Support for IND, IMPD, and BLA submissions. • Quality-by-Design (QbD) implementation and risk-based validation strategies. 5. Development & Technology Transfer • Process development and scale-up from R&D to GMP. • Tech transfer frameworks that minimize risk and timelines. • Collaborative team integration between client scientists and OcyonBio experts. Flexible Infrastructure Model OcyonBio offers a hybrid model that combines the benefits of a Contract Development and Manufacturing Organization (CDMO) with the autonomy of dedicated, client-operated space. Companies can lease customizable GMP suites, QC labs, and support areas within our purpose-built campus while accessing centralized services such as: • Centralized QA/QC and regulatory support • Supply chain and cold chain management • Utilities, warehousing, and environmental monitoring • Trained labor pool and technical assistance This unique model accelerates facility readiness while preserving control over critical manufacturing processes. Facilities OcyonBio’s 200,000+ square-foot campus in Aguadilla includes: • ISO 7/ISO 8 cleanrooms • Dedicated vector production suites • Aseptic filling lines with isolator technology • Analytical and QC laboratories • Office and training space for client teams • Modular expansion zones to meet growing capacity needs Puerto Rico offers a strategic geographic and regulatory advantage: U.S. jurisdiction, cost-effective labor, strong logistics, and significant tax incentives. Why Partner with OcyonBio? • Speed to Clinic and Market: Accelerated timelines through modular buildouts and technology transfer expertise. • Customized Engagement Models: From comprehensive CDMO services to co-located manufacturing partnerships. • Deep Expertise: Decades of experience across regulatory, operations, process development, and manufacturing. • Resilient Supply Chain: On-island capabilities minimize international shipping risks and ensure control over the supply chain. • Incentivized Operating Environment: Leverage Puerto Rico’s Act 60 incentives, workforce development programs, and export advantages. Your Partner from Discovery to Commercialization Whether you’re a biotech startup advancing a first-in-human product or an established biopharma seeking a strategic CGT manufacturing partner, OcyonBio offers the agility, infrastructure, and scientific depth to bring your innovations to life. Join us at BIO 2025 to explore how OcyonBio can support your next breakthrough.
NUVISAN
Your partner of choice in bringing therapeutics to life. Nuvisan is a full-service CRO and CDMO with state-of-the-art facilities in Germany and France, supporting pharmaceutical, biotech, venture capital and non-profit partners with high-quality, end-to-end solutions that accelerate the journey from early discovery to clinical development. With more than 40 years of heritage, Nuvisan has built a reputation for scientific excellence, industry expertise and seamless integration across discovery, development and manufacturing. Our centres of excellence, including drug discovery in Berlin, provide comprehensive capabilities to advance complex programs efficiently. In oncology, Nuvisan offers a comprehensive portfolio of specialised technologies and models designed to accelerate cancer therapeutic innovation. Our capabilities encompass target validation, CRISPR/RNAi screening, custom assay development, next-generation sequencing, single-cell analyses, multiplex flow cytometry, biomarker discovery and in vivo pharmacology including PK/PD and efficacy studies. With an extensive collection of cancer models and deep translational expertise, we support programs across solid tumours, hematologic malignancies, immuno-oncology and novel therapeutic modalities. By working collaboratively to adapt to each client’s unique needs, we help de-risk development and expedite the delivery of impactful oncology therapeutics to patients worldwide. | The NUVISAN group is a contract research and development and manufacturing organization (CRO/CDMO) with five sites in Germany and France as well as local experts situated in Latin America. We offer unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain to our biotech startup, pharma, non-profit, and venture capital clients – from target identification to the patient. With over 40 years of experience and a dedicated team of over 1,000 professionals, including more than 70% industry-experienced scientists and laboratory professionals, we possess the expertise to navigate the complexities of bringing innovative medicines to market. Recognizing the unique nature of each project, our teams prioritize flexible and innovative approaches and foster transparent communication to work closely with clients and effectively meet individual needs. | Your partner of choice in bringing therapeutics to life Nuvisan is a full-service contract research organisation (CRO) and development and manufacturing organisation (CDMO) with state-of-the-art laboratories in Germany and France. Our pharmaceutical, biotechnology, venture capital and non-profit clients partner with us because our high-quality end-to-end solutions and scientific expertise enable us to streamline and accelerate drug discovery and development – from ensuring target understanding to helping bring therapeutics to life. Founded over 40 years ago by a team of pharma industry innovators, Nuvisan has established a reputation for expertise and professionalism. Our team leaders have extensive experience in the biopharma industry, and our unique centres of excellence – for drug discovery in Berlin, formulation and GMP manufacturing in Sophia Antipolis, and our bioanalysis hub in Neu-Ulm – enable our experienced scientists to help guide and advance projects. We know how to discover, develop and bring the next generation of medicines to market. At the same time, we are committed to flexibility, transparency and collaboration in our approach, working closely with you to adapt to your individual needs, minimise risks and help deliver your project. Discovery: Helping you to achieve key decision milestones through deep scientific insights, innovation and collaboration. Preclinical: Enabling you to successfully develop and de-risk your preclinical candidates for a smooth transition to the clinic. CMC: Collaborating with you to advance molecules into drug products. Clinical: Providing tailored clinical solutions to fully assess your drug faster. Digital: Empowering your drug discovery and development with integrated data services, machine learning and generative AI. Research phases Supporting you with integrated, tailored solutions at every step of your drug discovery and development journey.
Nucleon Research Pvt Ltd
Nucleon Research, a leading global Clinical Research Organization (CRO) headquartered in the United States with active operations across India and Southeast Asia, is keen to explore potential strategic collaborations with your organization. We specialize in comprehensive clinical research services, including: Clinical Trials (Phases I–IV, Real-World Evidence & Investigator-Initiated Trials) Clinical Supplies & Packaging Clinical Manufacturing Standalone CDMO Services We believe our aligned visions present a unique opportunity to create significant mutual value through collaboration in clinical research initiatives across the USA, India, or Southeast Asia. We would welcome the opportunity to discuss how we might collaborate on upcoming clinical research initiatives. Contact @ BD@nucleonresearch.com
Novartis
x | About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. | Novartis Contract Manufacturing is a global contract manufacturing player in the biotech field and cell & gene therapy offering world class manufacturing services in the Novartis state of art facilities across USA, Europe and Singapore. We are committed to the highest quality standards. We are offering a fully integrated set of Contract Manufacturing Services and Solutions for various fields. Our capabilities are: • Microbial manufacturing: up to 13.000L scale • Mammalian manufacturing: up to 13.000L scale • Cell & Gene Therapy: Viral vector – adherent up to 500 m2, suspension up to 500L; Autologous cell therapy • Plasmid DNA: Small and large scale up to 1.300L • mRNA: Production at 150L scale (larger scales to be discussed) • siRNA & Antisense Oligonucleotides • Fill &Finish: Dropper bottles, Tubes, Low level siliconized Syringes, Vials (liquid, lyophilized)
NorthX Biologics
We offer services and support in the development and manufacturing of biologics used in vaccines, gene therapy and other advanced applications. Let’s journey together. | Nestled in Sweden’s life sciences heartland, NorthX Biologics has been at the forefront of biologics manufacturing and process development since 1992. Our rich heritage in Good Manufacturing Practice (GMP) is not just a testament to our enduring commitment to quality but also to the trust that the biotech community has placed in us for nearly three decades. Our expertise spans a comprehensive spectrum of biologics, including plasmids, proteins, mRNA, viral vectors cell therapy, and an array of other advanced therapeutic entities. It is our relentless pursuit of excellence and innovation that led to our recognition in 2021 as a national innovation hub for advanced therapeutics and vaccines by the Swedish Government, a milestone that underscores our role in shaping the future of healthcare. We are more than a CDMO; we are pioneers and partners in the truest sense. At NorthX Biologics, we believe in embarking on a collaborative journey with our clients, navigating the complexities of biologics and growing along the way. Let’s journey together to turn visionary science into life-changing treatments. Visit us to learn more at nxbio.com | Nestled in Sweden’s life sciences heartland, NorthX Biologics has been at the forefront of biologics manufacturing and process development since 1992. Our rich heritage in Good Manufacturing Practice (GMP) is not just a testament to our enduring commitment to quality but also to the trust that the biotech community has placed in us for nearly three decades. Our expertise spans a comprehensive spectrum of biologics, including plasmids, proteins, mRNA, viral vectors cell therapy, and an array of other advanced therapeutic entities. It is our relentless pursuit of excellence and innovation that led to our recognition in 2021 as a national innovation hub for advanced therapeutics and vaccines by the Swedish Government, a milestone that underscores our role in shaping the future of healthcare. We are more than a CDMO; we are pioneers and partners in the truest sense. At NorthX Biologics, we believe in embarking on a collaborative journey with our clients, navigating the complexities of biologics and growing along the way. Let’s journey together to turn visionary science into life-changing treatments.
Northway Biotech
Northway Biotech is a global end-to-end biologics CDMO supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company’s wide-ranging expertise and vertically integrated service offerings translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities, while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius (Lithuania) and Waltham, MA (USA). | Northway Biotech is a global end-to-end CDMO specializing in protein-based biologics and gene therapies. With over 20 years of experience and 180+ successful client programs, we provide integrated solutions – from cell line development to manufacturing cGMP Drug Substance and Drug Product. Our cGMP facilities in Vilnius, Lithuania, and Waltham, MA, support rapid, scalable manufacturing from early development through clinical and commercial phases. Known for scientific excellence, regulatory compliance, and a collaborative approach, Northway Biotech helps clients accelerate biopharmaceutical process development and manufacturing with speed, precision, and flexibility. | Northway Biotech is a leading biologics CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client’s unique needs. For further information, please visit www.northwaybiotech.com.